Researchers at the Korea Advanced Institute of Science and Technology (KAIST) have developed a novel method called “cancer reversion therapy”.
Unlike traditional therapies that destroy cancer cells, this method reprograms cancerous cells into normal-like cells.
They identified three key molecules—MYB, HDAC2, and FOXA2—as master regulators of cancer cell behavior.
Using digital twin modeling (a simulation technique that mimics real biological systems), scientists validated their approach before confirming its effectiveness through lab experiments in mice.
This strategy shows promise in reducing side effects and may be applicable beyond colon cancer, potentially transforming treatments for multiple cancer types.
Unlike traditional therapies that destroy cancer cells, this method reprograms cancerous cells into normal-like cells.
They identified three key molecules—MYB, HDAC2, and FOXA2—as master regulators of cancer cell behavior.
Using digital twin modeling (a simulation technique that mimics real biological systems), scientists validated their approach before confirming its effectiveness through lab experiments in mice.
This strategy shows promise in reducing side effects and may be applicable beyond colon cancer, potentially transforming treatments for multiple cancer types.
Researchers at the Korea Advanced Institute of Science and Technology (KAIST) have developed a novel method called “cancer reversion therapy”.
Unlike traditional therapies that destroy cancer cells, this method reprograms cancerous cells into normal-like cells.
They identified three key molecules—MYB, HDAC2, and FOXA2—as master regulators of cancer cell behavior.
Using digital twin modeling (a simulation technique that mimics real biological systems), scientists validated their approach before confirming its effectiveness through lab experiments in mice.
This strategy shows promise in reducing side effects and may be applicable beyond colon cancer, potentially transforming treatments for multiple cancer types.
0 Commentarii
0 Distribuiri
19K Views
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Portuguese (Brazil)
Greek
Arabic